136 related articles for article (PubMed ID: 24071829)
1. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.
Türbachova I; Schwachula T; Vasconcelos I; Mustea A; Baldinger T; Jones KA; Bujard H; Olek A; Olek K; Gellhaus K; Braicu I; Könsgen D; Fryer C; Ravot E; Hellwag A; Westerfeld N; Gruss OJ; Meissner M; Hasan MT; Weber M; Hoffmüller U; Zimmermann S; Loddenkemper C; Mahner S; Babel N; Berns E; Adams R; Zeilinger R; Baron U; Vergote I; Maughan T; Marme F; Dickhaus T; Sehouli J; Olek S
Epigenetics; 2013 Nov; 8(11):1226-35. PubMed ID: 24071829
[TBL] [Abstract][Full Text] [Related]
2. Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg.
Barth SD; Schulze JJ; Kühn T; Raschke E; Hüsing A; Johnson T; Kaaks R; Olek S
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26298011
[TBL] [Abstract][Full Text] [Related]
3. Correlation between tumor infiltrating immune cells and peripheral regulatory T cell determined using methylation analyses and its prognostic significance in resected gastric cancer.
Suh KJ; Kim JW; Kim JE; Sung JH; Koh J; Kim KJ; Kim JW; Ahn SH; Park DJ; Kim HH; Lee HS; Lee KW
PLoS One; 2021; 16(6):e0252480. PubMed ID: 34086741
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic quantification of tumor-infiltrating T-lymphocytes.
Sehouli J; Loddenkemper C; Cornu T; Schwachula T; Hoffmüller U; Grützkau A; Lohneis P; Dickhaus T; Gröne J; Kruschewski M; Mustea A; Turbachova I; Baron U; Olek S
Epigenetics; 2011 Feb; 6(2):236-46. PubMed ID: 20962591
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
6. A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer.
Löffler MW; Nussbaum B; Jäger G; Jurmeister PS; Budczies J; Pereira PL; Clasen S; Kowalewski DJ; Mühlenbruch L; Königsrainer I; Beckert S; Ladurner R; Wagner S; Bullinger F; Gross TH; Schroeder C; Sipos B; Königsrainer A; Stevanović S; Denkert C; Rammensee HG; Gouttefangeas C; Haen SP
Front Immunol; 2019; 10():2526. PubMed ID: 31803175
[No Abstract] [Full Text] [Related]
7. Laryngeal T regulatory cells in the setting of smoking and reflux.
Jetté ME; Seroogy CM; Thibeault SL
Laryngoscope; 2017 Apr; 127(4):882-887. PubMed ID: 27653511
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance.
Sun YF; Yang XR; Zhou J; Qiu SJ; Fan J; Xu Y
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1151-73. PubMed ID: 21681690
[TBL] [Abstract][Full Text] [Related]
9. Tim-3 expression defines regulatory T cells in human tumors.
Yan J; Zhang Y; Zhang JP; Liang J; Li L; Zheng L
PLoS One; 2013; 8(3):e58006. PubMed ID: 23526963
[TBL] [Abstract][Full Text] [Related]
10. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.
Gasparri ML; Savone D; Besharat RA; Farooqi AA; Bellati F; Ruscito I; Panici PB; Papadia A
Tumour Biol; 2016 Jan; 37(1):71-5. PubMed ID: 26500096
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin.
Remark R; Alifano M; Cremer I; Lupo A; Dieu-Nosjean MC; Riquet M; Crozet L; Ouakrim H; Goc J; Cazes A; Fléjou JF; Gibault L; Verkarre V; Régnard JF; Pagès ON; Oudard S; Mlecnik B; Sautès-Fridman C; Fridman WH; Damotte D
Clin Cancer Res; 2013 Aug; 19(15):4079-91. PubMed ID: 23785047
[TBL] [Abstract][Full Text] [Related]
13. Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer.
Ray M; Ruffalo MM; Bar-Joseph Z
Genes Chromosomes Cancer; 2019 Jan; 58(1):34-42. PubMed ID: 30285311
[TBL] [Abstract][Full Text] [Related]
14. Interaction among cells of bone, immune system, and solid tumors leads to bone metastases.
Roato I
Clin Dev Immunol; 2013; 2013():315024. PubMed ID: 23710201
[TBL] [Abstract][Full Text] [Related]
15. Tumor antigens and markers for breast and ovarian cancers.
Ghadersohi A; Chitta K; Greco WR; Harvey S; Winston J; Slocum H; Odunsi K; Sood AK
Front Biosci; 2002 Feb; 7():e48-57. PubMed ID: 11815284
[TBL] [Abstract][Full Text] [Related]
16. Phenotyping of immune cell infiltrates in breast and colorectal tumours.
Toomey D; Harmey J; Condron C; Kay E; Bouchier-Hayes D
Immunol Invest; 1999 Jan; 28(1):29-41. PubMed ID: 10073680
[TBL] [Abstract][Full Text] [Related]
17. CD4⁺ T cells expressing latency-associated peptide and Foxp3 are an activated subgroup of regulatory T cells enriched in patients with colorectal cancer.
Mahalingam J; Lin CY; Chiang JM; Su PJ; Chu YY; Lai HY; Fang JH; Huang CT; Lin YC
PLoS One; 2014; 9(9):e108554. PubMed ID: 25268580
[TBL] [Abstract][Full Text] [Related]
18. Increase of regulatory T cells in the peripheral blood of cancer patients.
Wolf AM; Wolf D; Steurer M; Gastl G; Gunsilius E; Grubeck-Loebenstein B
Clin Cancer Res; 2003 Feb; 9(2):606-12. PubMed ID: 12576425
[TBL] [Abstract][Full Text] [Related]
19. [Metastases to the breast from non-mammary malignancies: a clinicopathologic study of 28 cases].
Zhou S; Yu B; Cheng Y; Xu X; Shui R; Bi R; Lu H; Tu X; Yang W
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):231-5. PubMed ID: 24915812
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
